Roche and its unit Genentech have agreed to a global, exclusive licence agreement with Belgian company UCB to develop and commercialise an antibody treatment, UCB0107, for Alzheimer鈥檚 disease.
UCB0107 is an investigational monoclonal antibody that targets a central Tau epitope to inhibit or mitigate the spread of Tau pathology. It is being developed to potentially treat tauopathies such as progressive supranuclear palsy (PSP) and Alzheimer鈥檚.聽
As part of the agreement, UCB will provide Roche and Genentech with an exclusive licence to develop and commercialise the drug candidate in Alzheimer鈥檚 indication.
UCB executive vice-president Charl van Zyl said: 鈥淲e are excited that Roche and Genentech, with their deep and wide-ranging expertise, capacity and know-how in Alzheimer鈥檚 disease, will collaborate with UCB on UCB0107 with a shared ambition to offer people living with Alzheimer鈥檚 disease a new treatment option.”
Under the deal, UCB will get an initial upfront payment of $120m.
UCB will finance and conduct a proof-of-concept clinical trial in AD and after the study results are obtained, Genentech can choose to carry out the development or return full rights back to UCB.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIf Genentech decides to take up responsibility for further clinical development, UCB may receive cost reimbursement, development and sales milestones, as well as sales royalties, valued at a total of approximately $2bn.
Roche Pharma Partnering global head James Sabry said: “Our commitment remains strong on exploring multiple approaches with the hope that our research and development, including this collaboration with UCB, will lead to a disease-modifying medicine that could positively impact millions of people with Alzheimer鈥檚 disease.鈥� 聽
The transaction is subject to anti-trust clearance and other customary closing conditions.
Earlier this month, Roche forged a licensing and collaboration agreement with Blueprint Medicines for exclusive rights to co-develop and commercialise the latter鈥檚 cancer drug, pralsetinib, outside the US, except in Greater China.
As part of the deal, Blueprint Medicines and Roche unit Genentech will co-commercialise the cancer drug in the US.
